Caribou Biosciences (CRBU) Stock Forecast, Price Target & Predictions
CRBU Stock Forecast
Caribou Biosciences stock forecast is as follows: an average price target of $3.00 (represents a 51.52% upside from CRBU’s last price of $1.98) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
CRBU Price Target
The average price target for Caribou Biosciences (CRBU) is $3.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $3.00 to $3.00. This represents a potential 51.52% upside from CRBU's last price of $1.98.
CRBU Analyst Ratings
According to 3 Wall Street analysts, Caribou Biosciences's rating consensus is 'Buy'. The analyst rating breakdown for CRBU stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Caribou Biosciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 03, 2024 | Liisa Bayko | Evercore ISI | $3.00 | $2.88 | 4.17% | 51.52% |
The latest Caribou Biosciences stock forecast, released on Jun 03, 2024 by Liisa Bayko from Evercore ISI, set a price target of $3.00, which represents a 4.17% increase from the stock price at the time of the forecast ($2.88), and a 51.52% increase from CRBU last price ($1.98).
Caribou Biosciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $3.00 |
| Last Closing Price | $1.98 | $1.98 | $1.98 |
| Upside/Downside | -100.00% | -100.00% | 51.52% |
In the current month, the average price target of Caribou Biosciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Caribou Biosciences's last price of $1.98. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 04, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 14, 2024 | RBC Capital | Buy | Buy | Hold |
| Aug 14, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
| Jul 17, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jul 17, 2024 | Robert W. Baird | Underperform | Underperform | Hold |
| Jun 04, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 03, 2024 | Citigroup | Buy | Buy | Hold |
| May 16, 2024 | RBC Capital | Buy | Buy | Hold |
| May 16, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
| Feb 18, 2022 | RBC Capital | - | Outperform | Initialise |
Caribou Biosciences's last stock rating was published by H.C. Wainwright on Sep 04, 2024. The company gave CRBU a "Buy" rating, the same as its previous rate.
Caribou Biosciences Financial Forecast
Caribou Biosciences Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | $3.75M | $3.50M | $3.69M | $3.30M | $4.19M | $2.66M | $2.56M | $3.98M | $1.48M |
| Avg Forecast | $3.15M | $3.05M | $2.95M | $2.85M | $2.31M | $3.08M | $3.05M | $2.42M | $3.95M | $3.29M | $3.08M | $2.75M | $3.07M | $3.70M | $2.86M | $3.20M | $4.17M | $16.50M | $16.50M |
| High Forecast | $3.76M | $3.64M | $3.52M | $3.40M | $3.19M | $3.15M | $3.64M | $2.42M | $6.96M | $3.36M | $3.68M | $3.28M | $3.66M | $3.70M | $2.86M | $3.20M | $4.17M | $16.50M | $16.50M |
| Low Forecast | $2.69M | $2.61M | $2.52M | $2.44M | $1.84M | $3.01M | $2.61M | $2.42M | $2.68M | $3.22M | $2.63M | $2.35M | $2.62M | $3.70M | $2.86M | $3.20M | $4.17M | $16.50M | $16.50M |
| # Analysts | 1 | 1 | 1 | 1 | 4 | 2 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 1.22% | 1.27% | 1.20% | 0.89% | 1.47% | 0.83% | 0.61% | 0.24% | 0.09% |
Caribou Biosciences's average Quarter revenue forecast for Sep 23 based on 4 analysts is $3.29M, with a low forecast of $3.22M, and a high forecast of $3.36M. CRBU's average Quarter revenue forecast represents a -12.34% decrease compared to the company's last Quarter revenue of $3.75M (Jun 23).
Caribou Biosciences EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 4 | 2 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | $-32.87M | $-30.51M | $-30.52M | $-26.12M | $-28.06M | $-20.46M | $-17.90M | $-20.71M | $-14.08M |
| Avg Forecast | $-3.15M | $-3.05M | $-2.95M | $-2.85M | $-2.31M | $-3.08M | $-3.05M | $-2.42M | $-3.95M | $-3.29M | $-3.08M | $-2.75M | $-3.07M | $-3.70M | $-2.86M | $-20.39M | $-4.17M | $-820.27M | $-16.50M |
| High Forecast | $-2.69M | $-2.61M | $-2.52M | $-2.44M | $-1.84M | $-3.01M | $-2.61M | $-2.42M | $-2.68M | $-3.22M | $-2.63M | $-2.35M | $-2.62M | $-3.70M | $-2.86M | $-16.31M | $-4.17M | $-656.22M | $-16.50M |
| Low Forecast | $-3.76M | $-3.64M | $-3.52M | $-3.40M | $-3.19M | $-3.15M | $-3.64M | $-2.42M | $-6.96M | $-3.36M | $-3.68M | $-3.28M | $-3.66M | $-3.70M | $-2.86M | $-24.47M | $-4.17M | $-984.33M | $-16.50M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 10.68% | 11.10% | 9.95% | 7.06% | 9.81% | 1.00% | 4.29% | 0.03% | 0.85% |
undefined analysts predict CRBU's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Caribou Biosciences's previous annual EBITDA (undefined) of $NaN.
Caribou Biosciences Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 4 | 2 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 |
| Net Income | - | - | - | - | - | - | - | - | - | - | $-29.52M | $-24.99M | $-26.99M | $-26.76M | $-24.96M | $-17.32M | $-18.48M | $-20.97M | $-14.31M |
| Avg Forecast | $-46.13M | $-43.42M | $-40.71M | $-39.80M | $-38.57M | $-40.67M | $-41.43M | $-37.17M | $-33.25M | $-37.65M | $-44.76M | $-43.47M | $-41.75M | $-43.63M | $-32.81M | $-20.72M | $-32.32M | $-830.57M | $38.11M |
| High Forecast | $-37.47M | $-35.26M | $-33.06M | $-32.33M | $-35.81M | $-33.03M | $-33.65M | $-30.19M | $31.73M | $-30.58M | $-36.36M | $-35.31M | $-33.91M | $-43.63M | $-32.81M | $-16.58M | $-32.32M | $-664.46M | $38.11M |
| Low Forecast | $-57.80M | $-54.40M | $-51.00M | $-49.87M | $-42.24M | $-50.95M | $-51.90M | $-46.57M | $-66.49M | $-47.17M | $-56.08M | $-54.46M | $-52.31M | $-43.63M | $-32.81M | $-24.87M | $-32.32M | $-996.68M | $38.11M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.66% | 0.57% | 0.65% | 0.61% | 0.76% | 0.84% | 0.57% | 0.03% | -0.38% |
Caribou Biosciences's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CRBU's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Caribou Biosciences SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 4 | 2 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 |
| SG&A | - | - | - | - | - | - | - | - | - | - | $10.12M | $8.91M | $8.53M | $9.85M | $10.04M | $9.59M | $7.85M | $6.76M | $5.11M |
| Avg Forecast | $6.54M | $6.33M | $6.12M | $5.91M | $4.80M | $6.39M | $6.32M | $5.01M | $8.21M | $6.83M | $6.39M | $5.71M | $6.37M | $7.60M | $5.88M | $6.57M | $8.57M | $33.90M | $33.90M |
| High Forecast | $7.81M | $7.56M | $7.31M | $7.06M | $6.61M | $6.54M | $7.55M | $5.02M | $14.44M | $6.98M | $7.63M | $6.82M | $7.60M | $7.60M | $5.88M | $6.57M | $8.57M | $33.90M | $33.90M |
| Low Forecast | $5.59M | $5.41M | $5.24M | $5.06M | $3.82M | $6.24M | $5.41M | $5.01M | $5.55M | $6.68M | $5.46M | $4.88M | $5.45M | $7.60M | $5.88M | $6.57M | $8.57M | $33.90M | $33.90M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 1.58% | 1.56% | 1.34% | 1.30% | 1.71% | 1.46% | 0.92% | 0.20% | 0.15% |
Caribou Biosciences's average Quarter SG&A projection for Sep 23 is $6.83M, based on 4 Wall Street analysts, with a range of $6.68M to $6.98M. The forecast indicates a -32.50% fall compared to CRBU last annual SG&A of $10.12M (Jun 23).
Caribou Biosciences EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 4 | 2 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 |
| EPS | - | - | - | - | - | - | - | - | - | - | $-0.48 | $-0.41 | $-0.44 | $-0.44 | $-0.41 | $-0.29 | $-0.31 | $-0.46 | $-0.26 |
| Avg Forecast | $-0.51 | $-0.48 | $-0.45 | $-0.44 | $-0.43 | $-0.45 | $-0.46 | $-0.41 | $-0.37 | $-0.42 | $-0.49 | $-0.48 | $-0.46 | $-0.48 | $-0.36 | $-0.35 | $-0.36 | $-0.12 | $0.42 |
| High Forecast | $-0.41 | $-0.39 | $-0.37 | $-0.36 | $-0.40 | $-0.37 | $-0.37 | $-0.33 | $0.35 | $-0.34 | $-0.40 | $-0.39 | $-0.37 | $-0.48 | $-0.36 | $-0.35 | $-0.36 | $-0.12 | $0.42 |
| Low Forecast | $-0.64 | $-0.60 | $-0.56 | $-0.55 | $-0.47 | $-0.56 | $-0.57 | $-0.51 | $-0.74 | $-0.52 | $-0.62 | $-0.60 | $-0.58 | $-0.48 | $-0.36 | $-0.35 | $-0.36 | $-0.12 | $0.42 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.97% | 0.85% | 0.95% | 0.91% | 1.13% | 0.84% | 0.87% | 3.80% | -0.62% |
According to undefined Wall Street analysts, Caribou Biosciences's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CRBU previous annual EPS of $NaN (undefined).
Caribou Biosciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| FATE | Fate Therapeutics | $2.27 | $39.67 | 1647.58% | Buy |
| NTLA | Intellia Therapeutics | $14.17 | $115.90 | 717.93% | Buy |
| PRME | Prime Medicine | $3.18 | $17.25 | 442.45% | Buy |
| EDIT | Editas Medicine | $2.52 | $12.85 | 409.92% | Buy |
| VERV | Verve Therapeutics | $4.50 | $19.00 | 322.22% | Buy |
| SANA | Sana Bio | $2.34 | $8.00 | 241.88% | Buy |
| ADPT | Adaptive Bio | $4.68 | $12.33 | 163.46% | Hold |
| BEAM | Beam Therapeutics | $24.12 | $58.50 | 142.54% | Buy |
| CRSP | CRISPR Therapeutics | $47.30 | $101.46 | 114.50% | Buy |
| CRBU | Caribou Biosciences | $1.98 | $3.00 | 51.52% | Buy |